TAT 2017: Provisional program and confirmed speakers online

[TAT Congress <tat@congressbydesign.com>]

Title: *|MC:SUBJECT|*

View this email in your browser

The home of phase 1 in oncology Video of Prof. Jean-Charles Soria, President of TAT 2017 on the key characteristics of the 15th International Congress on Targeted Anticancer Therapies: Prof. Jean-Charles Soria, President of TAT 2017 Provisional program TAT 2017 Program at a glance: Monday, March 6, 09:00 - 19:00 Plenary Session 1: Opening Ceremony Plenary Session 2: Immuno-oncology (1) Plenary Session 3: Phase 1 Studies Plenary Session 4: New drugs in hemato-oncology Poster Awarding Ceremony Poster viewing & Welcome reception Tuesday, March 7, 08:30 - 17:50 Plenary Session 5: Immuno-oncology (2) Plenary Session 6: Targeting the cell cycle Plenary Session 7: Targeted drug delivery Plenary Session 8: Clinical genomic profiling in early-phase clinical studies Wednesday, March 8, 08:30 - 15:40 Plenary Session 9: Targeting cancer metabolism Plenary Session 10: Miscellaneous drugs and targets Plenary Session 11: DNA-targeted therapies Plenary Session 12: New targets in the androgen receptor pathway Full program Registration Join this highly targeted conference covering the most promising new drugs and cancer targets under development in early phase clinical and translational research, as well as drugs close to entering clinical development. Take advantage of our significantly reduced early registration fees until February 3, 2017. Go to the TAT Congress website now and save up to EUR 200 on your participation in one of the leading meetings on emerging innovations in systemic cancer therapy. Register here Call for abstracts Abstracts on a wide range of topics in the field of targeted therapy for cancer are invited. Submitted abstracts will undergo peer review. In general, accepted abstracts will be scheduled for poster presentation. However a number of selected abstracts will be scheduled for oral presentation in a plenary session. The deadline for abstract submission is January 6, 2017. Abstracts accepted for presentation will be published in an indexed oncology journal.  Submit your abstract

Organizing Committee Jean-Charles Soria, FR; President Giuseppe Giaccone, USA Gail Eckhardt, USA Lee Ellis, USA Marinus Lobbezoo, NL Josep Tabernero, ES Alexander Eggermont, FR Scientific Advisory Board Michael Atkins, USA Jean-Pierre Armand, FR Udai Banerji, UK Susan Bates, USA Philippe Bedard, CAN Hilary Calvert, UK Filippo de Braud, IT Kapil Dhingra, USA Keith Flaherty, USA Roch Houot, FR David Hyman, USA Jeffrey Infante, USA Antoine Italiano, FR Filip Janku, USA Shivaani Kummar, USA Ulrik Lassen, DK Martijn Lolkema, NL Patricia LoRusso, USA Aurelien Marabelle, FR Christophe Massard, FR Peter O’Dwyer, USA Arne Östman, SWE Michael Pishvaian, USA Ruth Plummer, UK Yves Pommier, USA Vincent Ribrag, FR Jordi Rodon, ES Gary Schwartz, USA Lesley Seymour, CAN Geoffrey Shapiro, USA Anthony Tolcher, USA Giorgio Trinchieri, USA John Wright, USA Confirmed speakers Susan Bates Columbia University Medical Center Daniel Chen Genentech Alexander Eggermont Gustave Roussy Cancer Giuseppe Giaccone Georgetown University Ignacio Melero University of Navarra Jean-Charles Soria Gustave Roussy Cancer Emile Voest Netherlands Cancer Institute Roman Yelensky Gritstone Oncology Sponsors & Exhibitors

To unscubcribe from future TAT mailings, click here.